^
    Back
    Association details:
    Biomarker:AR F877L
    Cancer:Prostate Cancer
    Drug:Xtandi (enzalutamide capsule) (Androgen receptor inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    J Med Chem
    Title:

    Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)

    Published date:
    01/20/2021
    Excerpt:
    The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide.
    DOI:
    10.1021/acs.jmedchem.0c01563